Crescita Therapeutics Inc (CTX : TSX)
Common Stock
$0.79
CAD
+0.00 (%)
Last updated: 2026-06-04
CTX
Crescita Therapeutics Inc
WealthAwesomePerformance
1 Day
+0.00%
1 Week
+0.00%
1 Month
+0.00%
YTD
+64.58%
Key Statistics
Market Cap
$14.71M
52W High
$0.79
52W Low
$0.40
P/E Ratio
-
50 Day MA
$0.75
200 Day MA
$0.55
Beta
-0.14
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/4/2026 | $0.79 | $0.79 | $0.79 | $0.79 | $0.79 | 1,164 |
| 6/3/2026 | $0.79 | $0.79 | $0.79 | $0.79 | $0.79 | 92,771 |
| 6/2/2026 | $0.79 | $0.79 | $0.79 | $0.79 | $0.79 | 4,646 |
| 6/1/2026 | $0.75 | $0.75 | $0.75 | $0.75 | $0.75 | 0 |
| 5/29/2026 | $0.75 | $0.75 | $0.75 | $0.75 | $0.75 | 0 |
| 5/28/2026 | $0.75 | $0.75 | $0.75 | $0.75 | $0.75 | 989 |
| 5/27/2026 | $0.75 | $0.75 | $0.75 | $0.75 | $0.75 | 0 |
| 5/26/2026 | $0.75 | $0.75 | $0.75 | $0.75 | $0.75 | 1,299 |
| 5/25/2026 | $0.75 | $0.75 | $0.75 | $0.75 | $0.75 | 0 |
| 5/22/2026 | $0.75 | $0.75 | $0.75 | $0.75 | $0.75 | 3,560 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CTX's historical volatility
30-Day Vol
16.4%
Annualized
90-Day Vol
80.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.94
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.84 | C$0.79 – C$0.89 |
| 60 trading days | C$0.89 | C$0.82 – C$0.96 |
| 90 trading days | C$0.94 | C$0.86 – C$1.04 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Crescita Therapeutics Inc
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary drug delivery platforms, which include Multiplexed Molecular Penetration Enhancers and DuraPee that supports the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures. Its non-prescription portfolio offers dermocosmetic products, such as face creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud and Aquafolia brands; and medical aesthetics under the Pro-Derm and Alyria brands for non-invasive and minimally invasive procedures or skincare treatments. The company also distributes Bacti Control, a solution for hand hygiene; NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; ART FILLER, a hyaluronic acid-based dermal filler; and MicronJet, an intradermal injection device. The company has commercialization license agreement with Cantabria Labs Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.
Financials
- Revenue (TTM)
- $23.22M
- EBITDA
- $-65,000
- Profit Margin
- -1.38%
- ROE (TTM)
- -2.19%
- EPS (Diluted)
- -0.01
- Book Value
- 0.78
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About CTX
Articles Featuring CTX.TO
Latest articles and analysis covering CTX.TO
